| pubmed-article:19914063 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:19914063 | lifeskim:mentions | umls-concept:C0087111 | lld:lifeskim |
| pubmed-article:19914063 | lifeskim:mentions | umls-concept:C0028754 | lld:lifeskim |
| pubmed-article:19914063 | lifeskim:mentions | umls-concept:C0243192 | lld:lifeskim |
| pubmed-article:19914063 | lifeskim:mentions | umls-concept:C0220781 | lld:lifeskim |
| pubmed-article:19914063 | lifeskim:mentions | umls-concept:C1883254 | lld:lifeskim |
| pubmed-article:19914063 | lifeskim:mentions | umls-concept:C1707689 | lld:lifeskim |
| pubmed-article:19914063 | pubmed:issue | 1 | lld:pubmed |
| pubmed-article:19914063 | pubmed:dateCreated | 2010-2-3 | lld:pubmed |
| pubmed-article:19914063 | pubmed:abstractText | Based on our original pyrazine hit, CP-0809101, novel conformationally-restricted 5HT2c receptor agonists with 2-piperazin-azaindane scaffold were designed. Synthesis and structure-activity relationship (SAR) studies are described with emphasis on optimization of the selectivity against 5HT2a and 5HT2b receptors with excellent 2c potency. Orally-active and selective compounds were identified with dose-responsive in vivo efficacy in our pre-clinical food intake model. | lld:pubmed |
| pubmed-article:19914063 | pubmed:language | eng | lld:pubmed |
| pubmed-article:19914063 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19914063 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:19914063 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19914063 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19914063 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19914063 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19914063 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19914063 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:19914063 | pubmed:month | Jan | lld:pubmed |
| pubmed-article:19914063 | pubmed:issn | 1464-3405 | lld:pubmed |
| pubmed-article:19914063 | pubmed:author | pubmed-author:GohY TYT | lld:pubmed |
| pubmed-article:19914063 | pubmed:author | pubmed-author:TomlinsonEliz... | lld:pubmed |
| pubmed-article:19914063 | pubmed:author | pubmed-author:BrownJaniceJ | lld:pubmed |
| pubmed-article:19914063 | pubmed:author | pubmed-author:LeeEunsunE | lld:pubmed |
| pubmed-article:19914063 | pubmed:author | pubmed-author:KongJimmy XJX | lld:pubmed |
| pubmed-article:19914063 | pubmed:author | pubmed-author:MaurerTristan... | lld:pubmed |
| pubmed-article:19914063 | pubmed:author | pubmed-author:CorneliusPete... | lld:pubmed |
| pubmed-article:19914063 | pubmed:author | pubmed-author:PattersonTerr... | lld:pubmed |
| pubmed-article:19914063 | pubmed:author | pubmed-author:LiuKevin... | lld:pubmed |
| pubmed-article:19914063 | pubmed:author | pubmed-author:MaralaRaviR | lld:pubmed |
| pubmed-article:19914063 | pubmed:author | pubmed-author:VageChandraC | lld:pubmed |
| pubmed-article:19914063 | pubmed:author | pubmed-author:WernerWendyW | lld:pubmed |
| pubmed-article:19914063 | pubmed:author | pubmed-author:SantucciSteph... | lld:pubmed |
| pubmed-article:19914063 | pubmed:author | pubmed-author:GibbonsCollee... | lld:pubmed |
| pubmed-article:19914063 | pubmed:author | pubmed-author:WenzelZaneZ | lld:pubmed |
| pubmed-article:19914063 | pubmed:copyrightInfo | Copyright 2009 Elsevier Ltd. All rights reserved. | lld:pubmed |
| pubmed-article:19914063 | pubmed:issnType | Electronic | lld:pubmed |
| pubmed-article:19914063 | pubmed:day | 1 | lld:pubmed |
| pubmed-article:19914063 | pubmed:volume | 20 | lld:pubmed |
| pubmed-article:19914063 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:19914063 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:19914063 | pubmed:pagination | 266-71 | lld:pubmed |
| pubmed-article:19914063 | pubmed:dateRevised | 2010-11-18 | lld:pubmed |
| pubmed-article:19914063 | pubmed:meshHeading | pubmed-meshheading:19914063... | lld:pubmed |
| pubmed-article:19914063 | pubmed:meshHeading | pubmed-meshheading:19914063... | lld:pubmed |
| pubmed-article:19914063 | pubmed:meshHeading | pubmed-meshheading:19914063... | lld:pubmed |
| pubmed-article:19914063 | pubmed:meshHeading | pubmed-meshheading:19914063... | lld:pubmed |
| pubmed-article:19914063 | pubmed:meshHeading | pubmed-meshheading:19914063... | lld:pubmed |
| pubmed-article:19914063 | pubmed:meshHeading | pubmed-meshheading:19914063... | lld:pubmed |
| pubmed-article:19914063 | pubmed:meshHeading | pubmed-meshheading:19914063... | lld:pubmed |
| pubmed-article:19914063 | pubmed:meshHeading | pubmed-meshheading:19914063... | lld:pubmed |
| pubmed-article:19914063 | pubmed:meshHeading | pubmed-meshheading:19914063... | lld:pubmed |
| pubmed-article:19914063 | pubmed:meshHeading | pubmed-meshheading:19914063... | lld:pubmed |
| pubmed-article:19914063 | pubmed:meshHeading | pubmed-meshheading:19914063... | lld:pubmed |
| pubmed-article:19914063 | pubmed:meshHeading | pubmed-meshheading:19914063... | lld:pubmed |
| pubmed-article:19914063 | pubmed:meshHeading | pubmed-meshheading:19914063... | lld:pubmed |
| pubmed-article:19914063 | pubmed:year | 2010 | lld:pubmed |
| pubmed-article:19914063 | pubmed:articleTitle | Design and synthesis of orally-active and selective azaindane 5HT2c agonist for the treatment of obesity. | lld:pubmed |
| pubmed-article:19914063 | pubmed:affiliation | Pfizer Global Research and Development, Chemistry Department, 10770 Science Center Drive, La Jolla, CA 92120, United States. kevin.k.liu@pfizer.com | lld:pubmed |
| pubmed-article:19914063 | pubmed:publicationType | Journal Article | lld:pubmed |
| http://linkedlifedata.com/r... | http://linkedlifedata.com/r... | pubmed-article:19914063 | lld:chembl |
